VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy

Conclusions These studies indicate that ZD6474, when used in conjunction with radiation therapy, has a clear therapeutic advantage, providing a rationale for considering the combination of this agent with radiotherapy in the clinic.